Biota Pharmaceuticals has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, France, for 3.5 million shares of Biota stock and $8.0 million in cash. The transaction also includes additional consideration of as much as $30 million based on clinical and regulatory milestones, plus a royalty. The transaction, subject to customary conditions, is expected to close April 2015.   Biota gains its lead candidate is AP611074, a direct-act...